Exelixis, Inc. (EXEL) Up 5.9% — Time to Allocate Capital Here?
Exelixis, Inc. (EXEL) surged 5.86% in today's session, adding $2.84 to close at $51.38 on the NASDAQ. The move was decisive and broad-based, carrying shares to within striking distance of their 52-week high of $52.96 set on May 28, 2026—just 3.0% above the current close and a level that now looks well within reach if momentum holds.
Trading volume came in at approximately 1.23 million shares against a 90-day average of roughly 2.77 million, running well below the typical pace. Despite the lighter turnover, the price action was clean and sustained throughout the session, suggesting the advance was driven by conviction rather than speculative noise.
Why Exelixis, Inc. Price is Moving Higher
Exelixis is benefiting from a powerful combination of catalysts that have been building over the past several weeks, and today's session looks like continued follow-through on genuinely strong operational news. The foundation is Q1 2026 results reported on April 30 that delivered a clean beat on both the top and bottom lines: revenue of $610.8 million, including $555.0 million in U.S. cabozantinib product revenue, represented roughly 40% growth versus the $425 million posted in Q1 2025. GAAP diluted EPS of $0.79 and non-GAAP EPS of $0.87 both came in sharply above year-ago figures in the mid-$0.40s range, demonstrating meaningful operating leverage as the company scales its flagship franchise.
Layered on top of the earnings momentum is a significant regulatory development: the FDA accepted Exelixis' New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer. That acceptance moves the company's lead pipeline asset materially closer to market and opens an entirely new commercial avenue beyond cabozantinib—an important inflection point for investors who have been watching to see whether Exelixis can build a multi-product oncology business. Management also used its earnings commentary to reinforce the zanzalintinib narrative directly, highlighting continued cash generation and a pipeline roadmap that gives analysts a cleaner line of sight into medium-term growth. Insider buying reported in late May adds a final vote of confidence from those with direct visibility into the business.
The valuation case is strengthening alongside the fundamentals. With a forward P/E of just 16.10 and a profit margin of 35.08%, Exelixis offers an unusual combination of deep profitability and reasonable pricing for a biotech in active pipeline expansion mode. For investors in the Health Care sector who are accustomed to paying premium multiples for growth, that setup deserves attention—particularly as the zanzalintinib NDA acceptance reduces binary pipeline risk and makes the growth profile more visible.
What is the Exelixis, Inc. Rating - Should I Buy?
Weiss Ratings assigns EXEL a B rating. Current recommendation is Buy. The overall grade reflects a business that is firing on multiple dimensions simultaneously, with the sub-index profile reinforcing the case for investors who want quality exposure in the Health Care sector.
ROE of 40.99% earns the Excellent Efficiency Index—an exceptional figure for an oncology-focused pharmaceutical company navigating the capital-intensive reality of drug development, clinical trials, and regulatory filings. Paired with revenue growth of 9.97% and a profit margin of 35.08%, both supporting the Excellent Growth Index, the picture that emerges is a company that has moved beyond the binary bet stage and is generating durable, high-quality earnings from a commercially established franchise. The Excellent Solvency Index rounds out the core positives, confirming that Exelixis carries its growth ambitions from a position of financial strength rather than balance sheet stress—a meaningful distinction in a sector where pipeline investment can strain weaker operators.
The Good Volatility Index acknowledges that EXEL can move meaningfully in either direction—a reality for any company with binary regulatory events still ahead—but does not flag the kind of erratic price behavior that would concern disciplined risk managers. The Fair Total Return Index reflects the stock's historical return profile relative to peers and serves as a reminder that sustained gains will require continued execution on both the cabozantinib franchise and the zanzalintinib approval timeline. These nuances are worth monitoring but do not undermine the overall Buy case.
Within the Health Care sector, EXEL sits alongside Johnson & Johnson (JNJ, B) and Amgen Inc. (AMGN, B), standing a step ahead of Eli Lilly and Company (LLY, B-), Gilead Sciences, Inc. (GILD, B-), and Vertex Pharmaceuticals Incorporated (VRTX, B-). That positioning places Exelixis among the higher-conviction Buy-rated names in large-cap Health Care—a peer group that investors in this space watch closely.
About Exelixis, Inc.
Exelixis, Inc. (EXEL) is a Health Care company operating within the Pharmaceuticals, Biotechnology and Life Sciences industry, built around the discovery, development, and commercialization of oncology therapies. The company's commercial engine is cabozantinib, a multi-targeted receptor tyrosine kinase inhibitor that has earned regulatory approvals across several tumor types, including renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. That breadth of approved indications, combined with ongoing clinical investigation into additional combinations and settings, has established cabozantinib as one of the more durable oncology franchises in the mid-cap pharmaceutical space.
Beyond its approved product, Exelixis has built a meaningful clinical pipeline centered on zanzalintinib, a next-generation tyrosine kinase inhibitor designed to improve on the activity profile of cabozantinib with an optimized selectivity. The FDA's acceptance of the NDA for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer represents the company's most advanced effort to establish a second commercial pillar—addressing a high-unmet-need cancer setting where treatment options remain limited. The combination approach reflects Exelixis' strategic intent to pair its kinase inhibitor expertise with checkpoint immunotherapy to amplify clinical benefit.
Exelixis operates with a business model that emphasizes disciplined capital allocation alongside pipeline investment, using its cabozantinib cash flows to fund development activities without compromising financial flexibility. The company's intellectual property around its kinase inhibitor chemistry, along with established relationships across academic medical centers, cooperative oncology groups, and global regulatory bodies, provides competitive advantages that are difficult to replicate quickly. Its focus on a single therapeutic area—oncology—allows for concentrated scientific and commercial expertise, enabling efficient clinical development and targeted market access strategies across an increasingly competitive cancer drug landscape.
Investor Outlook
Exelixis, Inc. (EXEL) carries a Weiss Rating of B (Buy), reflecting a business delivering high-margin growth from an established franchise while advancing a credible pipeline that has now cleared a key regulatory hurdle. Investors will want to monitor the zanzalintinib NDA review timeline closely, as approval would represent a material expansion of Exelixis' commercial opportunity and likely serve as the next major catalyst for the stock. With shares sitting just 3.0% below their 52-week high, the near-term test of that overhead resistance is the most immediate price level to watch. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--